These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31236813)

  • 1. Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
    Michel LL; Sommer L; González Silos R; Lorenzo Bermejo J; von Au A; Seitz J; Hennigs A; Smetanay K; Golatta M; Heil J; Schütz F; Sohn C; Schneeweiss A; Marmé F
    Breast Cancer Res Treat; 2019 Sep; 177(2):437-446. PubMed ID: 31236813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index.
    Michel LL; Sommer L; González Silos R; Lorenzo Bermejo J; von Au A; Seitz J; Hennigs A; Smetanay K; Golatta M; Heil J; Schütz F; Sohn C; Schneeweiss A; Marmé F
    PLoS One; 2019; 14(1):e0211337. PubMed ID: 30703111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
    Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
    Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.
    Loibl S; Weber K; Huober J; Krappmann K; Marmé F; Schem C; Engels K; Pfitzner BM; Kümmel S; Furlanetto J; Hartmann A; Darb-Esfahani S; Müller V; Staebler A; von Minckwitz G; Kronenwett R; Denkert C
    Clin Cancer Res; 2018 Jul; 24(14):3358-3365. PubMed ID: 29618617
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
    Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Abdelsattar JM; Al-Hilli Z; Hoskin TL; Heins CN; Boughey JC
    Ann Surg Oncol; 2016 Oct; 23(10):3206-11. PubMed ID: 27328945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
    Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
    JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
    Mittendorf EA; Jeruss JS; Tucker SL; Kolli A; Newman LA; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
    J Clin Oncol; 2011 May; 29(15):1956-62. PubMed ID: 21482989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis.
    Willner J; Kiricuta IC; Kölbl O
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):853-63. PubMed ID: 9128962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
    Soares ICS; Bello MA; Bergmann A; Thuler LCS
    Breast Cancer Res Treat; 2021 Jun; 187(2):547-555. PubMed ID: 33417086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
    Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
    Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
    Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS
    Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and pattern of failure following locoregional recurrence of breast cancer.
    Kamby C; Sengeløv L
    Clin Oncol (R Coll Radiol); 1999; 11(3):156-63. PubMed ID: 10465468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.